UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015855
Receipt number R000018410
Scientific Title Study on the improvement in exercise capacity in patients with inoperable chronic thromboembolic pulmonary hypertension who are treated with balloon pulmonary angioplasty
Date of disclosure of the study information 2015/01/01
Last modified on 2021/09/09 16:30:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on the improvement in exercise capacity in patients with inoperable chronic thromboembolic pulmonary hypertension who are treated with balloon pulmonary angioplasty

Acronym

Study on the improvement in exercise capacity in patients with inoperable chronic thromboembolic pulmonary hypertension who are treated with balloon pulmonary angioplasty

Scientific Title

Study on the improvement in exercise capacity in patients with inoperable chronic thromboembolic pulmonary hypertension who are treated with balloon pulmonary angioplasty

Scientific Title:Acronym

Study on the improvement in exercise capacity in patients with inoperable chronic thromboembolic pulmonary hypertension who are treated with balloon pulmonary angioplasty

Region

Japan


Condition

Condition

Chronic thromboembolic pulmonary hypertension

Classification by specialty

Cardiology Pneumology Radiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

A purpose is to verify the improvement in exercise capacity in patients with chronic thromboembolic pulmonary hypertension who are treated with balloon pulmonary angioplasty adding to guanylate cyclase stimulant treatment

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Exercise capacity by cardiopulmonary exercise test

Key secondary outcomes

vascular endothelial function, sympton, hemodynamics by right heart catheterization, biomarkers by laboratory test


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients diagnosed as inoperable chronic thromboembolic pulmonary hypertension
1-1 Pulmonary hypertension is confirmed with right heart catheterization (mean pulmonary arterial pressure is equal to or higher than 25 mmHg and pulmonary artery wedge pressure is equal to or less than 15 mmHg at rest).
1-2 Peripheral thrombus is confirmed in pulmonary artery in contrast CT or pulmonary angiography.
1-3 Segmental blood perfusion defect is comfirmed by ventilation-perfusion scintigraphy.
1-4 Inoperable judgement is performed by a surgeon with experience for pulmonary endarterectomy.
2. Patients with WHO functional class 2, 3 and 4
3. Patients who understand study details with written consents.

Key exclusion criteria

1. Pregnancy
2. History of allergic reaction to contrast medium
3. Cardiogenic shock
4. Severe liver dysfunction (Child-Pugh score C)
5. Renal dysfunction (serum creatinine levels is greater than or equal to 2.0 mg/dL)
6. Patients whose disadvantage in cardiopulmonary exercise test
(CPX) is greater than benefits among one with relative conraindications for CPX
7. Contraindications for CPX
8. Patients who cannot keep supine position
9. Left heart failure
10. Patients who have received balloon pulmonary angioplasty (BPA) at the point of entry

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kondo Takahisa

Organization

Nagoya University Graduate School of Medicine

Division name

Advanced Medicine in Cardiopulmonary disease

Zip code


Address

Turumai-cho 65, Showa-ku, Nagoya 466-8560, Japan

TEL

052-744-0388

Email

takahisa@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kondo Takahisa

Organization

Nagoya University Graduate School of Medicine

Division name

Advanced Medicine in Cardiopulmonary disease

Zip code


Address

Turumai-cho 65, Showa-ku, Nagoya 466-8560, Japan

TEL

052-744-0388

Homepage URL


Email

takahisa@med.nagoya-u.ac.jp


Sponsor or person

Institute

Nagoya University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Grant-in-Aid for Scientific Research

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2014 Year 12 Month 01 Day

Date of IRB


Anticipated trial start date

2015 Year 01 Month 01 Day

Last follow-up date

2020 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2021 Year 03 Month 31 Day


Other

Other related information

BPA is added to medical therapy. Change of exercise capacity is evaluated.


Management information

Registered date

2014 Year 12 Month 05 Day

Last modified on

2021 Year 09 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018410


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name